

**AMENDMENTS TO THE CLAIMS**

1. (currently amended): A method for treating an occult choroidal neovascular (CNV) lesion in a subject comprising  
selecting a subject with an occult CNV lesion comprising an occult component of >50% and <100% of the lesion and assessed as having either (a) a small lesion with a size less than 5 disc areas, or (b) poor visual acuity of less than 65 letters prior to treatment, or both (a) and (b); and  
providing photodynamic therapy (PDT) to the subject having said CNV lesion.
2. (original): The method of claim 1 wherein said subject was assessed by determining the size of said lesion and/or determining the best corrected visual acuity of the subject.
- 3-4. (canceled)
5. (previously presented): The method of claim 1 wherein the small lesion has a size less than 4 disc areas.
6. (previously presented): The method of claim 1, wherein said occult CNV lesion is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).
7. (original): The method of claim 1 wherein said PDT comprises the administration of a photosensitizer (PS).
8. (original): The method of claim 7, wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m<sup>2</sup> (PS/body surface area of subject).
9. (original): The method of claim 8, wherein the PS is administered at a concentration of 6 mg/m<sup>2</sup>.
10. (original): The method of claim 9, wherein the PS is a green porphyrin.

11. (original): The method of claim 10, wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.
12. (original): The method of claim 11, wherein the green porphyrin is BPD-MA.
13. (original): The method of claim 10, wherein the PS is coupled to a specific binding ligand.
14. (original): The method of claim 7, wherein the PS is formulated with a carrier.
15. (original): The method of claim 14, wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.
16. (original): The method of claim 1, wherein said PDT comprises irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.
17. (original): The method of claim 16, wherein the irradiation provides between  $12.5 \text{ J/cm}^2$  and  $100 \text{ J/cm}^2$ .
18. (original): The method of claim 17, wherein said irradiation occurs between 5 to 30 minutes after administration of a photosensitizer.
19. (original): The method of claim 7, wherein the PS is administered at a concentration ranging between about  $10 \text{ } \mu\text{g/kg}$  to  $100\text{mg/kg}$  (PS/body weight of subject).
20. (previously presented): The method of claim 1, wherein a resulting loss of visual acuity is less with treatment than without treatment.
21. (withdrawn): The method of claim 11, wherein the green porphyrin is EA6.